143 related articles for article (PubMed ID: 38478041)
1. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract][Full Text] [Related]
3. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
[TBL] [Abstract][Full Text] [Related]
4. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.
Hagens MJ; Stelwagen PJ; Veerman H; Rynja SP; Smeenge M; van der Noort V; Roeleveld TA; van Kesteren J; Remmers S; Roobol MJ; van Leeuwen PJ; van der Poel HG
World J Urol; 2023 Jan; 41(1):13-18. PubMed ID: 36245015
[TBL] [Abstract][Full Text] [Related]
5. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
6. External Validation of the Rotterdam Prostate Cancer Risk Calculator and Comparison with Stockholm3 for Prostate Cancer Diagnosis in a Swedish Population-based Screening Cohort.
Palsdottir T; Grönberg H; Hilmisson A; Eklund M; Nordström T; Vigneswaran HT
Eur Urol Focus; 2023 May; 9(3):455-462. PubMed ID: 36522257
[TBL] [Abstract][Full Text] [Related]
7. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJU Int; 2024 Mar; 133(3):278-288. PubMed ID: 37607322
[TBL] [Abstract][Full Text] [Related]
8. Phi-based risk calculators performed better in the prediction of prostate cancer in the Chinese population.
Wu YS; Fu XJ; Na R; Ye DW; Qi J; Lin XL; Liu F; Gong J; Zhang N; Jiang GL; Jiang HW; Ding Q; Xu J; Sun YH
Asian J Androl; 2019; 21(6):592-597. PubMed ID: 30924451
[TBL] [Abstract][Full Text] [Related]
9. Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation.
De Nunzio C; Lombardo R; Baldassarri V; Cindolo L; Bertolo R; Minervini A; Sessa F; Muto G; Bove P; Vittori M; Bozzini G; Castellan P; Mugavero F; Falsaperla M; Schips L; Celia A; Bada M; Porreca A; Pastore A; Al Salhi Y; Giampaoli M; Novella G; Rizzetto R; Trabacchin N; Mantica G; Pini G; Remmers S; Antonelli A; Tubaro A
Eur J Surg Oncol; 2021 Oct; 47(10):2640-2645. PubMed ID: 33965292
[TBL] [Abstract][Full Text] [Related]
10. Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data.
Remmers S; Kasivisvanathan V; Verbeek JFM; Moore CM; Roobol MJ;
Eur Urol Open Sci; 2022 Feb; 36():1-8. PubMed ID: 35098168
[TBL] [Abstract][Full Text] [Related]
11. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.
Pereira-Azevedo N; Verbeek JFM; Nieboer D; Bangma CH; Roobol MJ
Transl Androl Urol; 2018 Feb; 7(1):18-26. PubMed ID: 29594016
[TBL] [Abstract][Full Text] [Related]
13. Risk-based Patient Selection for Magnetic Resonance Imaging-targeted Prostate Biopsy after Negative Transrectal Ultrasound-guided Random Biopsy Avoids Unnecessary Magnetic Resonance Imaging Scans.
Alberts AR; Schoots IG; Bokhorst LP; van Leenders GJ; Bangma CH; Roobol MJ
Eur Urol; 2016 Jun; 69(6):1129-34. PubMed ID: 26651990
[TBL] [Abstract][Full Text] [Related]
14. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
15. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
16. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts.
Drost FH; Nieboer D; Morgan TM; Carroll PR; Roobol MJ;
Eur Urol; 2019 Nov; 76(5):693-702. PubMed ID: 31451332
[TBL] [Abstract][Full Text] [Related]
17. Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
Hogenhout R; Osses DF; Alberts AR; Buizer-Rijksen HG; Remmers S; Roobol MJ
BJU Int; 2023 May; 131(5):596-601. PubMed ID: 36408660
[TBL] [Abstract][Full Text] [Related]
18. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy.
Pallauf M; Steinkohl F; Zimmermann G; Horetzky M; Rajwa P; Pradere B; Lindner AK; Pichler R; Kunit T; Shariat SF; Lusuardi L; Drerup M
World J Urol; 2022 Oct; 40(10):2451-2457. PubMed ID: 35941246
[TBL] [Abstract][Full Text] [Related]
19. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
[TBL] [Abstract][Full Text] [Related]
20. Improving multivariable prostate cancer risk assessment using the Prostate Health Index.
Foley RW; Gorman L; Sharifi N; Murphy K; Moore H; Tuzova AV; Perry AS; Murphy TB; Lundon DJ; Watson RW
BJU Int; 2016 Mar; 117(3):409-17. PubMed ID: 25847734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
